Review




Structured Review

Celladon Inc serca2a aav1
Gene therapy approaches in various neurological disorders
Serca2a Aav1, supplied by Celladon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav1%2Eserca2a/aav1+serca2a/pmc08518903-384-7-0
Average 90 stars, based on 1 article reviews
serca2a aav1 - by Bioz Stars, 2026-11
90/100 stars

Images

1) Product Images from "Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases"

Article Title: Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases

Journal: Molecular Neurobiology

doi: 10.1007/s12035-021-02555-y

Gene therapy approaches in various neurological disorders
Figure Legend Snippet: Gene therapy approaches in various neurological disorders

Techniques Used: Transgenic Assay, Mouse Assay, Over Expression, Inhibition, Activity Assay, Migration, Expressing, Functional Assay, Activation Assay, Plasmid Preparation, Injection, Recombinant, shRNA, CRISPR

Related Articles

other:

Article Title: Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure
Article Snippet: R.J.H. is the scientific cofounder of Celladon Corporation, which is developing AAV1.SERCA2a for the treatment of HF.

Article Title: The Role of SUMO-1 in Cardiac Oxidative Stress and Hypertrophy
Article Snippet: Dr Hajjar is the scientific cofounder of Celladon Corporation, which is developing AAV1.SERCA2a for the treatment of heart failure.

Article Title: Gene Therapy for the Treatment of CPVT
Article Snippet: Conflict of Interest Disclosures: RJH is the scientific co-founder of Celladon Co. which is developing AAV1.SERCA2a for the treatment of heart failure.

Article Title: Effect of Bortezomib on the Efficacy of AAV9.SERCA2a Treatment to Preserve Cardiac Function in a Rat Pressure-Overload Model of Heart Failure
Article Snippet: Conflict of Interest Dr. Hajjar is the scientific cofounder of Celladon, which plans to commercialize AAV1.SERCA2a for the treatment of heart failure.

Article Title: High-dose chloroquine is metabolically cardiotoxic by inducing lysosomes and mitochondria dysfunction in a rat model of pressure overload hypertrophy
Article Snippet: Roger Hajjar is a scientific founder of Celladon Co., which plans to commercialize AAV1.SERCA2a for the treatment of heart failure.

Article Title: Synergistic Role of Protein Phosphatase Inhibitor 1 and SERCA2a in the Acquisition of the Contractile Phenotype of Arterial Smooth Muscle Cells
Article Snippet: Journal Subject Codes: [162] Smooth muscle proliferation and differentiation, [130] Animal models of human disease, [123] Restenosis, [88] Gene therapy Conflict of Interest Disclosures: RJH is a scientific founder of Celladon Corp., which plans to commercialize AAV1.SERCA2a for the treatment of heart failure.

Article Title: Adeno-associated virus-mediated gene therapy in cardiovascular disease
Article Snippet: Conflicts of interest R.J.H. is a cofounder of Celladon, which is developing AAV1.SERCA2a for the treatment of heart failure.

Article Title: Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure.
Article Snippet: Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests: R.J.H. is the scientific cofounder of Celladon Corporation, which is developing AAV1.SERCA2a for the treatment of HF.



Similar Products

90
Celladon Inc serca2a aav1
Gene therapy approaches in various neurological disorders
Serca2a Aav1, supplied by Celladon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav1%2Eserca2a/aav1+serca2a/pmc08518903-384-7-0
Average 90 stars, based on 1 article reviews
serca2a aav1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
uniQure Inc aav1.serca2a
Gene therapy approaches in various neurological disorders
Aav1.Serca2a, supplied by uniQure Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav1%2Eserca2a/glybera+alipogene+tiparvovec/pmc07544018-169-8-16
Average 90 stars, based on 1 article reviews
aav1.serca2a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Celladon Inc aav1/serca2a
<t> AAV1 </t> NAb titers in non-immunosuppressed and immunosuppressed mini-pigs
Aav1/Serca2a, supplied by Celladon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav1%2Eserca2a/aav1+serca2a/pmc06558655-198-34-36
Average 90 stars, based on 1 article reviews
aav1/serca2a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Celladon Inc aav1/serca2a vials
<t> AAV1 </t> NAb titers in non-immunosuppressed and immunosuppressed mini-pigs
Aav1/Serca2a Vials, supplied by Celladon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav1%2Eserca2a/aav1+serca2a/pm28393439-34-2-7
Average 90 stars, based on 1 article reviews
aav1/serca2a vials - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Celladon Inc aav1.serca2a
<t> AAV1 </t> NAb titers in non-immunosuppressed and immunosuppressed mini-pigs
Aav1.Serca2a, supplied by Celladon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav1%2Eserca2a/aav1+serca2a/pmc05999331-467-36-30
Average 90 stars, based on 1 article reviews
aav1.serca2a - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Targeted Genetics Corporation aav1/serca2a tgabg12
<t> AAV1 </t> NAb titers in non-immunosuppressed and immunosuppressed mini-pigs
Aav1/Serca2a Tgabg12, supplied by Targeted Genetics Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aav1%2Eserca2a/aav1+serca2a+tgabg12/pmc05843948-204-6-13
Average 90 stars, based on 1 article reviews
aav1/serca2a tgabg12 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Gene therapy approaches in various neurological disorders

Journal: Molecular Neurobiology

Article Title: Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases

doi: 10.1007/s12035-021-02555-y

Figure Lengend Snippet: Gene therapy approaches in various neurological disorders

Article Snippet: Celladon utilized intracoronary infusion to administer the SERCA2A AAV1 product, whereas UniQure utilizes retro-infusion as well as left anterior descending coronary occlusion [ , ].

Techniques: Transgenic Assay, Mouse Assay, Over Expression, Inhibition, Activity Assay, Migration, Expressing, Functional Assay, Activation Assay, Plasmid Preparation, Injection, Recombinant, shRNA, CRISPR

 AAV1  NAb titers in non-immunosuppressed and immunosuppressed mini-pigs

Journal: Gene therapy

Article Title: Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure

doi: 10.1038/gt.2015.109

Figure Lengend Snippet: AAV1 NAb titers in non-immunosuppressed and immunosuppressed mini-pigs

Article Snippet: Three of the 39 patients enrolled in this trial seroconverted to detectable NAb levels between NAb screening (up to 6 months before day of dosing) and day 0, and received a single infusion of AAV1/SERCA2a (MYDICAR, Celladon Corporation, San Diego, CA, USA) or placebo.

Techniques: Control